| Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis WI McDonald, A Compston, G Edan, D Goodkin, HP Hartung, FD Lublin, ... Annals of Neurology: Official Journal of the American Neurological …, 2001 | 9445 | 2001 |
| Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, L Kappos, ... Annals of Neurology: Official Journal of the American Neurological …, 2005 | 6703 | 2005 |
| Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study G Comi, M Filippi, F Barkhof, L Durelli, G Edan, O Fernández, HP Hartung, ... The Lancet 357 (9268), 1576-1582, 2001 | 1496 | 2001 |
| Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ... Neurology 64 (7), 1144-1151, 2005 | 1105 | 2005 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 1053 | 2018 |
| Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller, ... Neurology 67 (7), 1242-1249, 2006 | 1032 | 2006 |
| Natural history of multiple sclerosis with childhood onset C Renoux, S Vukusic, Y Mikaeloff, G Edan, M Clanet, B Dubois, ... New England Journal of Medicine 356 (25), 2603-2613, 2007 | 758 | 2007 |
| Evidence for a two-stage disability progression in multiple sclerosis E Leray, J Yaouanq, E Le Page, M Coustans, D Laplaud, J Oger, G Edan Brain 133 (7), 1900-1913, 2010 | 751 | 2010 |
| Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the … L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ... The Lancet 370 (9585), 389-397, 2007 | 737 | 2007 |
| Vitamin D as an early predictor of multiple sclerosis activity and progression A Ascherio, KL Munger, R White, K Köchert, KC Simon, CH Polman, ... JAMA neurology 71 (3), 306-314, 2014 | 713 | 2014 |
| Epidemiology of multiple sclerosis E Leray, T Moreau, A Fromont, G Edan Revue neurologique 172 (1), 3-13, 2016 | 661 | 2016 |
| Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled … L Kappos, G Comi, H Panitch, J Oger, J Antel, P Conlon, L Steinman, ... Nature medicine 6 (10), 1176-1182, 2000 | 610 | 2000 |
| Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. G Edan, D Miller, M Clanet, C Confavreux, O Lyon-Caen, C Lubetzki, ... Journal of Neurology, Neurosurgery & Psychiatry 62 (2), 112-118, 1997 | 589 | 1997 |
| Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 … L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ... The Lancet Neurology 8 (11), 987-997, 2009 | 468 | 2009 |
| Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring L Kappos, D Bates, G Edan, M Eraksoy, A Garcia-Merino, N Grigoriadis, ... The Lancet Neurology 10 (8), 745-758, 2011 | 380 | 2011 |
| Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci NA Patsopoulos, ... Annals of neurology 70 (6), 897-912, 2011 | 370 | 2011 |
| MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study A Tourbah, C Lebrun-Frenay, G Edan, M Clanet, C Papeix, S Vukusic, ... Multiple Sclerosis Journal 22 (13), 1719-1731, 2016 | 349 | 2016 |
| Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study B Stankoff, E Waubant, C Confavreux, G Edan, M Debouverie, ... Neurology 64 (7), 1139-1143, 2005 | 347 | 2005 |
| Lack of association between antimyelin antibodies and progression to multiple sclerosis J Kuhle, C Pohl, M Mehling, G Edan, MS Freedman, HP Hartung, ... New England Journal of Medicine 356 (4), 371-378, 2007 | 311 | 2007 |
| Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab PS Sørensen, A Bertolotto, G Edan, G Giovannoni, R Gold, E Havrdova, ... Multiple Sclerosis Journal 18 (2), 143-152, 2012 | 309 | 2012 |
Olivier CommowickInria research scientist at Irisa, Rennes, FranceVerified email at inria.fr
